AWM Investment Company Inc. Decreases Stake in argenex SE $ARGX

AWM Investment Company Inc. decreased its position in argenex SE (NASDAQ:ARGX) by 34.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,000 shares of the company’s stock after selling 8,000 shares during the quarter. AWM Investment Company Inc.’s holdings in argenex were worth $8,268,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Franklin Resources Inc. increased its position in shares of argenex by 103.9% during the 2nd quarter. Franklin Resources Inc. now owns 279,803 shares of the company’s stock valued at $154,233,000 after purchasing an additional 142,606 shares during the last quarter. Millennium Management LLC lifted its stake in argenex by 316.9% in the first quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock worth $158,977,000 after purchasing an additional 204,180 shares during the last quarter. Jennison Associates LLC grew its stake in shares of argenex by 6.1% during the second quarter. Jennison Associates LLC now owns 264,647 shares of the company’s stock valued at $145,879,000 after buying an additional 15,186 shares during the last quarter. Orbimed Advisors LLC raised its holdings in shares of argenex by 0.6% in the second quarter. Orbimed Advisors LLC now owns 208,000 shares of the company’s stock worth $114,654,000 after buying an additional 1,300 shares during the period. Finally, American Century Companies Inc. lifted its stake in shares of argenex by 38.3% during the 2nd quarter. American Century Companies Inc. now owns 205,906 shares of the company’s stock worth $113,503,000 after acquiring an additional 57,054 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on ARGX shares. TD Cowen lifted their target price on argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Deutsche Bank Aktiengesellschaft cut shares of argenex from a “buy” rating to a “hold” rating in a research report on Thursday, September 11th. Piper Sandler upped their target price on shares of argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Guggenheim reaffirmed a “buy” rating and set a $1,070.00 price target on shares of argenex in a research note on Thursday, September 18th. Finally, HC Wainwright lifted their target price on argenex from $774.00 to $915.00 and gave the company a “buy” rating in a research report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $968.83.

argenex Stock Down 1.3%

Shares of NASDAQ:ARGX opened at $877.94 on Friday. The company has a market capitalization of $54.05 billion, a price-to-earnings ratio of 37.70, a price-to-earnings-growth ratio of 0.89 and a beta of 0.37. The firm has a 50 day moving average of $863.28 and a 200 day moving average of $716.27. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.37 by $0.03. The business had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.07 billion. argenex had a return on equity of 29.78% and a net margin of 41.58%. On average, sell-side analysts expect that argenex SE will post 3.13 EPS for the current year.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.